Antibody-Nanoparticle Conjugates
Closed Pre-Solicitation Posted
- Solicitation number
- 1301172257
- Agency
-
Naval Supply Systems Command
Department of the Navy, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 611310 Colleges, Universities, and Professional Schools
- PSC
- Q301 Reference Laboratory Testing
- Place of performance
- Chicago, Illinois 60637, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
This Pre-Solicitation Notice describes the Naval Medical Research Command's (NMRC) intent to award a sole source, firm-fixed-price purchase order to the University of Chicago for the production of nanoparticle-antibody conjugates. NMRC requires engineered nanoparticles coated with anti-dengue monoclonal antibodies for targeted delivery to inhibit dengue virus infection. The University of Chicago's Dr. Huang's lab has unique qualifications, with demonstrated in vitro and in vivo data showing their photothermal nanoparticles can inhibit SARS-CoV-2, and the ability to coat the nanoparticles with anti-viral antibodies for targeted delivery. The intended order is for a six-month performance period, with the contractor required to deliver the antibody-nanoparticle conjugates 4-24 weeks from receipt of the government-provided monoclonal antibody.
This procurement will be conducted as a sole source purchase under simplified acquisition procedures, with an estimated value of $50,000 for a one-year award. There is no set-aside designation, and the University of Chicago is the only known source that can meet the technical requirements. Interested parties may identify their interests and capabilities within 15 calendar days of the notice publication, but any response must show clear and convincing evidence that competition would be advantageous to the government.
Notice text
NOTICE OF INTENT TO AWARD A SOLE SOURCE
This Notice of Intent is not a request for competitive quotes. This is not a solicitation or request for offers. No solicitation package is available and telephone requests will not be honored. Only one responsible source and no other supplies or services will satisfy agency requirements.
Under the authority of FAR 13.106-1(b); circumstances of the contract action deem only one source reasonably available, Naval Medical Research Command (NMRC) intends to award a sole source, other than commercial product or commercial service, Firm-Fixed-Priced puchase order to The University of Chicago.
The intended order is for procurement of services to produce nanoparticle-antibody conjugates by linking a dengue monoclonal antibody to a nanoparticle to inhibit dengue infection and ship to NMRC. The production shall be within the performance period of six (6) months. The contractor shall deliver the ANC products 4-24 weeks from the receipt of the monoclonal antibody received from the government.
There are a variety of Nanoparticles in the market; each has its own chemical or biological composition. Lipid nanoparticles can encapsulate drugs which is a common strategy to deliver drug to infected cells. However, encapsulating drugs inside the nanoparticles is an additional and technically challenging step compared to nanoparticles possessing anti-viral property. Metal nanoparticles are another class of nanoparticles with anti-viral nature; however, most reports on metal nanoparticles were at in vitro stage as very few of them proceeded to in vivo animal stage. The work performed by Dr. Huang’s study at the University of Chicago had both in vitro and in vivo data showing how the photothermal nanoparticles his lab made can inhibit SARS-CoV-2 both in vitro in cells and in vivo in mice. In addition, Dr. Huang’s lab coated the nanoparticles with anti-SARS-CoV-2 antibodies which helped for targeted delivery of the nanoparticles to infected cell. These photothermal nanoparticles can absorb lights and emit energies to kill the virus.
This purchase will be made utilizing Simplified Acquisition Procedures in accordance with: Federal Acquisition Regulation (FAR) Part 13.106-1(b) for purchases not exceeding the simplified acquisition threshold of $250,000. Interested parties may identify their interests and capability with response to this requirement within fifteen (15) calendar days of the publication of this notice. Any response to this notice must show clear and convincing evidence that competition would be advantageous to the Government. Information received will be considered solely for the purpose of determining whether or not to conduct a competitive procurement. A determination by the Government not to compete this proposed purchase order based upon response to this notice is solely within the discretion of the Government. No reimbursement for any cost connected with providing capability information will be provided.
Files
| File | Type | Posted |
|---|---|---|
| ANC UoC J and A_..pdf |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| NOI - A Non-Invasive Prognostic Biomarker | Office of Logisitics and Acquisition Operations | No set-aside | |
| NOI - A Non-Invasive Prognostic Biomarker - Circul | Office of Logisitics and Acquisition Operations | No set-aside | |
| Intent to Sole Source - Medical/Scientific Instruments for the Department of Transfusion Medicine, NIH Clinical Center | National Institutes of Health | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity